C Diff Molecular

/PRNewswire/ -- Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name...

Nature - Enterococci enhance the fitness and pathogenesis of Clostridioides difficile in the gut by altering the amino acid composition and providing signals that increase its virulence towards the...

Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat.

Researchers have found that Enterococcus -- an antibiotic-resistant, opportunistic pathogen -- works together with C. difficile, reshaping and enhancing the metabolic environment in the gut so that C. difficile can thrive.

In recent years, both postpartum women and healthy adults have seen increased risk for CDI. #cdiff #cdiffawarenessmonth #seecdiff #seecdiffclearly— Peggy Lillis Fund (@PeggyFund) November 9, 2022

Nature Communications - Toxin B (TcdB) is a major exotoxin responsible for diseases associated with C. difficile infection. Here, Tian et al. show that several TcdB subtypes do not recognize the...

Clostridioides (Clostridium) difficile is a well-known cause of enteritis and antibiotic-associated diarrhea. Extraintestinal C. difficile infection is uncommon, with most extraintestinal infections involving the intra-abdominal cavity and anatomic structures adjacent to the colon. Emp …

Clostridioides difficile infection (CDI) is responsible for an increasing number of cases of post-antibiotic diarrhea worldwide, which has high severity and mortality among hospitalized elderly patients. The disruption of gut microbiota due to antibacterial medication facilitates the intestin …

Toxin B (TcdB) is a major exotoxin responsible for diseases associated with Clostridioides difficile infection. Its sequence variations among clinical isolates may contribute to the difficulty in developing effective therapeutics. Here, we investigate receptor-binding specificity of major TcdB subty …

Just one month before friends and families gather around the Christmas table, November is here to bring awareness around Clostridioides difficile infection, and the importance of microbiota-derived treatments

Emerging technologies are in the pipeline for better exploring the microbiome. @nsegata et al. have developed a computational pipeline that was used to interrogate a massively expanded dataset of metagenome and virome assemblies https://t.co/KlczhHSdSD— GutMicrobiota Health (@GMFHx) November 11, 2022

A two-plasmid mutagenesis system for Clostridioides difficile is described that improves ease of use and efficiency in creating site-directed mutations. pJB06 contains a xylose-inducible cas9 gene, while the second plasmid (pJB07) encodes the corresponding guide RNA (gRNA) and regions of homo …

ISME Communications - Predicting the re‐distribution of antibiotic molecules caused by inter‐species interactions in microbial communities

Among patients with CDI, CRE coinfections were associated with prolonged hospitalization for CDI. Age was an independent risk factor for CRE coinfection among patients with CDI.

Clostridioides (Clostridium) difficile is a well-known cause of enteritis and antibiotic-associated diarrhea. Extraintestinal C. difficile infection is uncommon, with most extraintestinal infections involving the intra-abdominal cavity and anatomic structures adjacent to the colon. Emp …

Nature Microbiology - Metagenomics and metabolomics analysis of a longitudinal cohort of 123 very preterm infants reveals multiple drivers of gut microbiome development and indicates that there are...

Nature Communications - Here, the authors show that SARS-CoV-2 infection causes gut microbiome dysbiosis and gut epithelial cell alterations in a mouse model, and correlate dysbiosis observed in...

According to a new study, a COVID infection can reduce the number of bacterial species in the gut, creating an opportunity for dangerous antibiotic-resistant bacteria to thrive.

Receptor-binding proteins (RBPs) are located at the viral tail and mediate the initial recognition of phage to a specific bacterial host. Phage RBPs have co-evolved with numerous types of host receptors resulting in the formation of a diverse assortment of cognate pairs of RBP-receptors that functio …

Background: The 2016 cumulative incidence of Clostridioides difficile infection (CDI) in Spain was reported by the European Center for Disease Control to be above the mean of other European countries. The aim of this multicenter prospective observational cohort study was to examine the …

Clinical severity of CDI influences the stool microbiome of infected patients. To date, this study has the largest data set comparing 16S rRNA microbiome profiles and clinical variables between CDI-infected and noninfected individuals.

The results of the present study highlighted the importance of SlpA in the pathogenesis of CDI and C. difficile-induced inflammatory response in the gut. Further studies are required to unravel the significance of the observed results in promoting the intestinal inflammation and immune response indu …

More than ever, the COVID-19 pandemic required strong up-to-date treatment recommendations to decrease the rate of serious in-hospital complications. Further studies are required to evaluate the interplay between COVID-19 and CDI/toxic megacolon.

Clostridioides difficile (C. difficile), is a major cause of nosocomial diarrhea and colitis. C. difficile flagellin FliC contributes toxins to gut inflammation by interacting with the immune Toll-like receptor 5 (TLR5) to activate nuclear factor-kappa B (NF-kB) and mitogen-acti …

Clostridioides difficile is Gram-positive spore-former bacterium and the leading cause of nosocomial antibiotic-associated diarrhea. During disease, C. difficile forms metabolically dormant spores that persist in the host and contribute to recurrence of the disease. The outermost surfa …

Webinar Series on Clostridioides difficile (C.difficile) Clostridioides (previously known as Clostridium) difficile (C. difficile) is a key cause of healthcare-associated infections and poses a substantial public health threat that carries high morbidity and mortality rates, especially amongst affected elderly patients (more than 65 years). C. difficile infection (CDI) also places a considerable burden on healthcare systems worldwide, with up to one-third of patients who develop an initial episode of CDI subsequently going on to develop a recurrence. While there is widespread scientific literature regarding CDI, there is still a need to better inform the wider medical community on the importance of recognising the microbiome-mediated nature of CDI and how different treatment modalities available can help to resolve the condition and/or restore the gut microbiota to avoid recurrence. In a series of 7 webinar ESNM and GMFH develop a full picture of the C. difficile infection (CDI) reaching from the importance of a healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches. The course is held by a distinguished Faculty with expertise in the fields of neurogastroenterology, functional gastrointestinal disorders and microbiota. ESNM aim is to promote the dissemination of information and stimulate interesting live discussions that would ultimately improve the healthcare of our patients.

Infectious enteritis is common in patients with inflammatory bowel disease (IBD). This case presented a young woman who underwent remission maintenance therapy for ulcerative colitis (UC). She was suspected of having concomitant Clostridioides difficile and Edwardsiella tarda infections. The patient …

Clostridioides difficile infection (CDI) is a gastro-intestinal (GI) infection that illustrates how perturbations in symbiotic host-microbiome interactions render the GI tract vulnerable to the opportunistic pathogens. CDI also serves as an example of how such perturbations could be reversed via gut …

A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).